Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Int. J. Mol. Sci. 2014, 15(4), 6046-6061; doi:10.3390/ijms15046046
Article

PSMA, EpCAM, VEGF and GRPR as Imaging Targets in Locally Recurrent Prostate Cancer after Radiotherapy

1,†
, 1,†
, 1
, 2
, 3
 and 1,*
Received: 24 January 2014; in revised form: 28 March 2014 / Accepted: 28 March 2014 / Published: 10 April 2014
(This article belongs to the Special Issue Molecular Research in Urology 2014)
View Full-Text   |   Download PDF [1557 KB, uploaded 19 June 2014]
Abstract: In this retrospective pilot study, the expression of the prostate-specific membrane antigen (PSMA), the epithelial cell adhesion molecule (EpCAM), the vascular endothelial growth factor (VEGF) and the gastrin-releasing peptide receptor (GRPR) in locally recurrent prostate cancer after brachytherapy or external beam radiotherapy (EBRT) was investigated, and their adequacy for targeted imaging was analyzed. Prostate cancer specimens were collected of 17 patients who underwent salvage prostatectomy because of locally recurrent prostate cancer after brachytherapy or EBRT. Immunohistochemistry was performed. A pathologist scored the immunoreactivity in prostate cancer and stroma. Staining for PSMA was seen in 100% (17/17), EpCAM in 82.3% (14/17), VEGF in 82.3% (14/17) and GRPR in 100% (17/17) of prostate cancer specimens. Staining for PSMA, EpCAM and VEGF was seen in 0% (0/17) and for GRPR in 100% (17/17) of the specimens’ stromal compartments. In 11.8% (2/17) of cases, the GRPR staining intensity of prostate cancer was higher than stroma, while in 88.2% (15/17), the staining was equal. Based on the absence of stromal staining, PSMA, EpCAM and VEGF show high tumor distinctiveness. Therefore, PSMA, EpCAM and VEGF can be used as targets for the bioimaging of recurrent prostate cancer after EBRT to exclude metastatic disease and/or to plan local salvage therapy.
Keywords: prostate cancer; immunohistochemistry; PSMA; EpCAM; VEGF; GRPR prostate cancer; immunohistochemistry; PSMA; EpCAM; VEGF; GRPR
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Rybalov, M.; Ananias, H.J.K.; Hoving, H.D.; van der Poel, H.G.; Rosati, S.; de Jong, I.J. PSMA, EpCAM, VEGF and GRPR as Imaging Targets in Locally Recurrent Prostate Cancer after Radiotherapy. Int. J. Mol. Sci. 2014, 15, 6046-6061.

AMA Style

Rybalov M, Ananias HJK, Hoving HD, van der Poel HG, Rosati S, de Jong IJ. PSMA, EpCAM, VEGF and GRPR as Imaging Targets in Locally Recurrent Prostate Cancer after Radiotherapy. International Journal of Molecular Sciences. 2014; 15(4):6046-6061.

Chicago/Turabian Style

Rybalov, Maxim; Ananias, Hildo J.K.; Hoving, Hilde D.; van der Poel, Henk G.; Rosati, Stefano; de Jong, Igle J. 2014. "PSMA, EpCAM, VEGF and GRPR as Imaging Targets in Locally Recurrent Prostate Cancer after Radiotherapy." Int. J. Mol. Sci. 15, no. 4: 6046-6061.


Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert